Symphony Financial Ltd. Co. Sells 8,002 Shares of Intuitive Surgical, Inc. $ISRG

Symphony Financial Ltd. Co. cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 69.8% during the third quarter, Holdings Channel.com reports. The fund owned 3,459 shares of the medical equipment provider’s stock after selling 8,002 shares during the period. Symphony Financial Ltd. Co.’s holdings in Intuitive Surgical were worth $1,549,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. SteelPeak Wealth LLC increased its holdings in shares of Intuitive Surgical by 28.7% in the third quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock worth $18,781,000 after purchasing an additional 9,364 shares during the last quarter. Eastover Investment Advisors LLC raised its stake in shares of Intuitive Surgical by 204.8% in the second quarter. Eastover Investment Advisors LLC now owns 13,163 shares of the medical equipment provider’s stock valued at $7,153,000 after acquiring an additional 8,844 shares during the period. Amalgamated Bank boosted its stake in shares of Intuitive Surgical by 2.2% during the 2nd quarter. Amalgamated Bank now owns 81,542 shares of the medical equipment provider’s stock worth $44,311,000 after purchasing an additional 1,772 shares during the period. Bessemer Group Inc. grew its holdings in Intuitive Surgical by 89.3% during the 2nd quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock valued at $428,386,000 after purchasing an additional 371,806 shares during the last quarter. Finally, Sax Wealth Advisors LLC lifted its stake in Intuitive Surgical by 218.1% in the second quarter. Sax Wealth Advisors LLC now owns 2,456 shares of the medical equipment provider’s stock worth $1,334,000 after purchasing an additional 1,684 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 0.3%

Shares of ISRG opened at $523.99 on Friday. The company has a 50 day moving average of $562.32 and a two-hundred day moving average of $511.79. The company has a market cap of $187.84 billion, a price-to-earnings ratio of 66.41, a price-to-earnings-growth ratio of 4.28 and a beta of 1.67. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.18% and a net margin of 28.38%.The company had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. During the same period in the prior year, the company posted $2.21 EPS. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near‑term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid‑teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating‑leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long‑term optionality: Early imaging data from the JURA feasibility study and a new 20 million‑patient da Vinci milestone reinforce long‑term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross‑margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross‑margin decline vs. recent quarters — a medium‑term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in‑line/hold (Evercore, Zacks), creating near‑term debate over valuation vs. growth and muting upside for traders focused on short‑term catalysts. The Fly: Evercore lowers price target

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Gary S. Guthart sold 22,806 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $570.89, for a total transaction of $13,019,717.34. Following the sale, the insider owned 2,694 shares in the company, valued at approximately $1,537,977.66. The trade was a 89.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig H. Barratt sold 750 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total value of $435,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 55,714 shares of company stock worth $31,617,799 in the last quarter. 0.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ISRG has been the topic of several recent analyst reports. Royal Bank Of Canada raised their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Argus lifted their price target on shares of Intuitive Surgical from $600.00 to $630.00 in a research note on Monday, October 27th. Citigroup reissued a “neutral” rating and issued a $590.00 price objective (down previously from $635.00) on shares of Intuitive Surgical in a research note on Friday. Wells Fargo & Company lifted their target price on Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, Raymond James Financial increased their price target on Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $617.57.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.